MCID: HGH043
MIFTS: 45

High Grade Glioma

Categories: Bone diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for High Grade Glioma

MalaCards integrated aliases for High Grade Glioma:

Name: High Grade Glioma 12 37
Malignant Glioma 12 54 6 15
Malignant Neuroglial Tumor 12
Glioma, Malignant 12
Malignant Gliomas 15
Glial Cell Tumor 12
Neuroglial Tumor 12
Glioma 44

Classifications:



External Ids:

Disease Ontology 12 DOID:3070
MeSH 44 D005910
NCIt 50 C4822
SNOMED-CT 67 393564001 74532006
UMLS 71 C0017638 C0555198

Summaries for High Grade Glioma

Disease Ontology : 12 A cell type cancer that has material basis in glial cells and is located in brain or located in spine.

MalaCards based summary : High Grade Glioma, also known as malignant glioma, is related to glioma and glioma susceptibility 1. An important gene associated with High Grade Glioma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways is Glioma. The drugs Midazolam and Trametinib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial.

Related Diseases for High Grade Glioma

Diseases related to High Grade Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1021)
# Related Disease Score Top Affiliating Genes
1 glioma 32.5 PVT1 NEAT1 HOXA11-AS HOTAIR GAS5 CYTOR
2 glioma susceptibility 1 32.0 CYTOR CDKN2B-AS1 CCDC26 CASC2
3 glioblastoma 31.7 XIST TUG1 PWAR5 MIR155HG HOXA-AS3 HOTAIRM1
4 thyroid carcinoma 30.7 PVT1 NEAT1 HOTAIR GAS5 CDKN2B-AS1 CASC2
5 leukemia, acute myeloid 30.6 TUG1 HOTAIRM1 HOTAIR CDKN2B-AS1 CCDC26 ATM
6 retinitis pigmentosa 11 30.3 XIST TUG1 PVT1 NEAT1 HOTAIR GAS5
7 b-cell lymphoma 30.3 TUG1 PVT1 HOTAIR GAS5 ATM
8 squamous cell carcinoma 30.3 TUG1 NEAT1 HOTAIR CDKN2B-AS1
9 renal cell carcinoma, nonpapillary 30.2 TUG1 PVT1 HOTAIR GAS5 CYTOR CRNDE
10 laryngeal squamous cell carcinoma 30.2 NEAT1 HOXA11-AS HOTAIR CDKN2B-AS1
11 esophageal cancer 30.2 XIST PVT1 HOXA11-AS HOTAIR GAS5 CYTOR
12 burkitt lymphoma 30.2 PVT1 NEAT1 MIR155HG ATM
13 myeloma, multiple 30.2 TUG1 PVT1 HOTAIR GAS5 ATM
14 bladder cancer 30.1 XIST TUG1 PVT1 HOTAIR GAS5 CDKN2B-AS1
15 melanoma 30.1 XIST PVT1 HOXA-AS2 HOTAIRM1 HOTAIR GAS5
16 lung cancer susceptibility 3 30.1 TUG1 HOTAIR GAS5 CYTOR CASC2
17 acute promyelocytic leukemia 30.1 PVT1 NEAT1 HOXA-AS2 HOTAIRM1
18 nasopharyngeal carcinoma 30.1 XIST PVT1 NEAT1 HOTAIR GAS5 CDKN2B-AS1
19 thyroid cancer, nonmedullary, 1 30.0 PVT1 NEAT1 HOTAIR
20 osteogenic sarcoma 30.0 XIST TUG1 PVT1 NEAT1 HOXA11-AS HOTAIR
21 cervical cancer 29.9 TUG1 PVT1 NEAT1 HOXA11-AS HOTAIR GAS5
22 pancreatic ductal adenocarcinoma 29.9 PVT1 HOTAIRM1 HOTAIR
23 pancreatic cancer 29.8 XIST TUG1 PVT1 NEAT1 HOTAIR GAS5
24 gallbladder cancer 29.8 TUG1 HOXA-AS2 HOTAIR CYTOR CRNDE CDKN2B-AS1
25 ovarian cancer 29.8 XIST TUG1 PVT1 NEAT1 HOXA11-AS HOTAIR
26 gastric cancer 29.8 XIST TUG1 PVT1 NEAT1 HOXA11-AS HOXA-AS2
27 leukemia 29.8 NEAT1 HOTAIRM1 HOTAIR GAS5 CDKN2B-AS1 ATM
28 hepatocellular carcinoma 29.8 XIST TUG1 PVT1 NEAT1 HOXA11-AS HOXA-AS2
29 hematologic cancer 29.8 XIST PVT1 CCDC26 ATM
30 prostate cancer 29.7 XIST TUG1 PVT1 NEAT1 HOTAIR GAS5
31 retinitis pigmentosa 29.7 XIST TUG1 PVT1 NEAT1 HOTAIR GAS5
32 kidney cancer 29.7 PVT1 HOTAIR GAS5
33 breast cancer 29.6 XIST TUG1 PVT1 NEAT1 HOXA11-AS HOXA-AS2
34 colorectal cancer 29.6 XIST TUG1 PVT1 NEAT1 HOXA11-AS HOXA-AS2
35 glial tumor 11.4
36 childhood brain stem glioma 11.4
37 optic pathway glioma 11.4
38 glioma susceptibility 2 11.4
39 glioma susceptibility 3 11.3
40 third ventricle chordoid glioma 11.3
41 chordoid glioma 11.2
42 limbic encephalitis with lgi1 antibodies 11.2
43 subependymal glioma 11.2
44 spinal cord glioma 11.2
45 childhood optic nerve glioma 11.1
46 adult brain stem glioma 11.1
47 glioma susceptibility 8 11.1
48 glioma susceptibility 4 11.1
49 adult brainstem mixed glioma 11.1
50 high grade ependymoma 11.1

Graphical network of the top 20 diseases related to High Grade Glioma:



Diseases related to High Grade Glioma

Symptoms & Phenotypes for High Grade Glioma

Drugs & Therapeutics for High Grade Glioma

Drugs for High Grade Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 476)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Trametinib Approved Phase 4 871700-17-3 11707110
3
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
4
Lactitol Approved, Investigational Phase 4 585-86-4 157355
5
Levetiracetam Approved Phase 4 102767-28-2 441341
6
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
7
Phenobarbital Approved, Investigational Phase 4 50-06-6 4763
8
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
9
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
10
Lacosamide Approved Phase 4 860352-01-8, 175481-36-4 219078
11
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
12
Topiramate Approved Phase 4 97240-79-4 5284627
13
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
14
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
15
Rufinamide Approved Phase 4 106308-44-5 129228
16
Clobazam Approved, Illicit Phase 4 22316-47-8 2789
17
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
18 Anticonvulsants Phase 4
19 Protein Kinase Inhibitors Phase 4
20 Antipsychotic Agents Phase 4
21 Anti-Anxiety Agents Phase 4
22 Calcium, Dietary Phase 4
23 Sodium Channel Blockers Phase 4
24 Diuretics, Potassium Sparing Phase 4
25 Hypoglycemic Agents Phase 4
26 calcium channel blockers Phase 4
27 Hypnotics and Sedatives Phase 4
28 GABA Modulators Phase 4
29 Excitatory Amino Acid Antagonists Phase 4
30 GABA Agonists Phase 4
31
Calcium Nutraceutical Phase 4 7440-70-2 271
32
leucovorin Approved Phase 3 58-05-9 6006
33
Dextroamphetamine Approved, Illicit Phase 3 51-64-9 5826
34
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
35
Ifosfamide Approved Phase 3 3778-73-2 3690
36
Trioxsalen Approved Phase 3 3902-71-4 5585
37
Carmustine Approved, Investigational Phase 3 154-93-8 2578
38
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
39
Dalteparin Approved Phase 3 9005-49-6
40
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
41
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
42
Somatostatin Approved, Investigational Phase 2, Phase 3 51110-01-1, 38916-34-6 53481605
43
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
44
Vinblastine Approved Phase 3 865-21-4 13342 241903
45
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
46
Ethanol Approved Phase 2, Phase 3 64-17-5 702
47
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
48
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
49
Bevacizumab Approved, Investigational Phase 3 216974-75-3
50
Lomustine Approved, Investigational Phase 3 13010-47-4 3950

Interventional clinical trials:

(show top 50) (show all 1187)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
3 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
4 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
5 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
6 A Phase IV, Prospective, Open-Label, Parallel Study Evaluating the Effect of an Adjunctive Anti-Seizure Medication Using a Glutamatergic Modulator in Patients With Focal Epilepsy and High-Grade Glioma Not yet recruiting NCT04650204 Phase 4 Phenobarbital, Phenytoin, Carbamazepine, Valproate, Gabapentin, Pregabalin, Lamotrigine, Topiramate, Leviteracetam, Lacosamide, Zonisamide, Clobazam, Oxcarbezepine, Rufinamide;Perampanel
7 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
8 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
9 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
10 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
11 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
12 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
13 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
14 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
15 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
16 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
17 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
18 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
19 A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) Completed NCT00135876 Phase 3 dalteparin
20 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
21 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
22 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
23 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
24 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
25 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma Completed NCT01781468 Phase 3 armodafinil 150 mg;armodafinil 250 mg
26 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
27 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
28 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
29 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
30 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
31 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
32 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
33 EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
34 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid
35 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
36 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Recruiting NCT03633552 Phase 3 Temozolomide
37 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
38 Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery Recruiting NCT04316039 Phase 2, Phase 3 Temozolomide
39 IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study Recruiting NCT03763422 Phase 3 Temozolomide
40 Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy - A Prospective Follow-up Study Recruiting NCT03534050 Phase 2, Phase 3
41 A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) Recruiting NCT03871257 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
42 A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Recruiting NCT02455245 Phase 3 Carboplatin;Vincristine
43 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Recruiting NCT04164901 Phase 3 AG-881;Matching Placebo
44 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Recruiting NCT04166409 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
45 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
46 A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial. Recruiting NCT02444000 Phase 3 PCV chemotherapy alone;Radiotherapy+PCV chemotherapy
47 Interest of Fluorescein in Fluorescence-guided Resection of Gliomas: A Randomized Study Recruiting NCT03291977 Phase 3 Fluorescéine Sodique Faure
48 A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Recruiting NCT04576117 Phase 3 Selumetinib Sulfate;Vinblastine Sulfate
49 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Active, not recruiting NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
50 3.0T High-field Intraoperative MRI Guided Extent of Resection in Cerebral Glioma Surgery: a Single Center Prospective Randomized Triple-blind Controlled Clinical Trial Active, not recruiting NCT01479686 Phase 3

Search NIH Clinical Center for High Grade Glioma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about High Grade Glioma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for High Grade Glioma:
ALD-451, bone marrow-derived cells for malignant glioma
Embryonic/Adult Cultured Cells Related to High Grade Glioma:
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905

Cochrane evidence based reviews: glioma

Genetic Tests for High Grade Glioma

Anatomical Context for High Grade Glioma

MalaCards organs/tissues related to High Grade Glioma:

40
Brain, T Cells, Endothelial, Bone Marrow, Spinal Cord, Cortex, Bone

Publications for High Grade Glioma

Articles related to High Grade Glioma:

(show top 50) (show all 8001)
# Title Authors PMID Year
1
Combination therapy with Gamma Knife radiosurgery and antisense EGFR for malignant glioma in vitro and orthotopic xenografts. 61 54
20428813 2010
2
Gene expression profiling predicts response to temozolomide in malignant gliomas. 61 54
20428759 2010
3
Akt signaling pathway: a target for radiosensitizing human malignant glioma. 61 54
20406894 2010
4
Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma. 54 61
19893595 2010
5
Review: on TRAIL for malignant glioma therapy? 54 61
20102513 2010
6
MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. 61 54
20204284 2010
7
Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression. 54 61
20188714 2010
8
Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation. 61 54
19939880 2010
9
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. 61 54
20167811 2010
10
Caffeine confers radiosensitization of PTEN-deficient malignant glioma cells by enhancing ionizing radiation-induced G1 arrest and negatively regulating Akt phosphorylation. 54 61
20103602 2010
11
Bevacizumab is active as a single agent against recurrent malignant gliomas. 54 61
20332478 2010
12
MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience. 61 54
19856394 2010
13
PAX6 suppression of glioma angiogenesis and the expression of vascular endothelial growth factor A. 61 54
19618119 2010
14
Astrocyte elevated gene-1: a novel target for human glioma therapy. 54 61
20053777 2010
15
Evaluation of the prognostic value of CD44 in glioblastoma multiforme. 54 61
20150644 2010
16
Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. 54 61
19875977 2009
17
The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. 54 61
19409438 2009
18
Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. 61 54
19398149 2009
19
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. 61 54
19332770 2009
20
Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. 61 54
19300910 2009
21
MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. 54 61
19536818 2009
22
Nuclear factor I regulates brain fatty acid-binding protein and glial fibrillary acidic protein gene expression in malignant glioma cell lines. 54 61
19540848 2009
23
Hypoxia up-regulates vascular endothelial growth factor in U-87 MG cells: involvement of TRPC1. 61 54
19446005 2009
24
Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. 61 54
19637006 2009
25
Effect of IFN-beta on human glioma cell lines with temozolomide resistance. 54 61
19513561 2009
26
Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. 54 61
19465936 2009
27
Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. 54 61
19416948 2009
28
Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations. 54 61
19567132 2009
29
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. 54 61
19435839 2009
30
Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2. 61 54
19429088 2009
31
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. 61 54
19248046 2009
32
KAAD-cyclopamine augmented TRAIL-mediated apoptosis in malignant glioma cells by modulating the intrinsic and extrinsic apoptotic pathway. 61 54
19385057 2009
33
Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. 54 61
18949017 2009
34
Downregulating FPR restrains xenograft tumors by impairing the angiogenic potential and invasive capability of malignant glioma cells. 61 54
19233142 2009
35
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. 61 54
19293187 2009
36
Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. 61 54
19252415 2009
37
Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis. 61 54
19356600 2009
38
Activation of telomerase by human cytomegalovirus. 61 54
19318640 2009
39
Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. 54 61
19212678 2009
40
Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes. 54 61
18785269 2009
41
cDNA clone, prokaryotic expression and purification of human interleukin-13 receptor [alpha]2 chain. 61 54
18677476 2009
42
Stress response of a p53 homologue in the radioresistant Sf9 insect cells. 54 61
19296337 2009
43
17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. 61 54
19027068 2009
44
The regulating role of mutant IkappaBalpha in expression of TIMP-2 and MMP-9 in human glioblastoma multiform. 61 54
19187648 2009
45
Targeted therapies for malignant glioma: progress and potential. 61 54
19344189 2009
46
Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. 61 54
20192118 2009
47
Novel anti-angiogenic therapies for malignant gliomas. 54 61
19007739 2008
48
Combination therapy for malignant glioma based on PTEN status. 61 54
18983237 2008
49
Antiangiogenic therapy in malignant gliomas. 61 54
18841047 2008
50
Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. 61 54
19067488 2008

Variations for High Grade Glioma

ClinVar genetic disease variations for High Grade Glioma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ATM NM_000051.3(ATM):c.8786+1G>A SNV Pathogenic 127463 rs17174393 11:108224608-108224608 11:108353881-108353881

Copy number variations for High Grade Glioma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 74684 13 110300000 115169878 Deletion Malignant glioma
2 75161 13 16300000 19500000 Deletion Malignant glioma
3 75381 13 19500000 32200000 Deletion Malignant glioma
4 77097 13 40100000 45200000 Deletion Malignant glioma
5 178248 3 69788586 70017488 Amplification MITF Malignant glioma

Expression for High Grade Glioma

Search GEO for disease gene expression data for High Grade Glioma.

Pathways for High Grade Glioma

Pathways related to High Grade Glioma according to KEGG:

36
# Name Kegg Source Accession
1 Glioma hsa05214

GO Terms for High Grade Glioma

Sources for High Grade Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....